You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

924 Results
Document
Jul 2021
Document
Jul 2021
Document
Jul 2021
Drug
Other Name(s): Piqray®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jun 2024
Document
Sep 2021
Document
Sep 2021
Document
Sep 2021
Document
Sep 2021
Document
Sep 2021
Document
Oct 2021
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant
Funding:
Exceptional Access Program
    olaparib - For the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated, human epidermal growth factor receptor 2-negative high risk early breast cancer, based on criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
olaparib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Dec 2024
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
New Drug Funding Program
    Brentuximab Vedotin - In Combination with Chemotherapy for Previously Untreated Advanced Stage Hodgkin Lymphoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
DOXOrubicin,
vinBLAStine,
dacarbazine,
brentuximab vedotin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2025

Pages